Oncology
HR+/HER2- Early Breast Cancer
Conference Reporter® in HR+/HER2- Early Breast Cancer to Cover Key Topics Being Presented at ASCO 2025
Conference Reporter delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. Conference Reporter will feature community-selected experts and topics in HR+/HER2- Early Breast Cancer presented at the 2025 ASCO Annual Meeting.
VIEW THE TOPICS:
• Adjuvant Systemic Therapy for Early-stage HR+/HER2- Breast Cancer
• CDK4/6 Inhibitor Therapy in Early-stage HR+/HER2- Breast Cancer
• Considerations for Treating Older Adults With Early-stage HR+/HER2- Breast Cancer
• Gene Expression Profiling for Early-stage HR+/HER2- Breast Cancer
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
2025 ASCO Annual Meeting
May 30 – June 3, 2025
McCormick Place, Chicago, IL & Online
Explore More in HR+/HER2- Early Breast Cancer
HR+/HER2- Early Breast Cancer